SG Americas Securities LLC Trims Stock Holdings in Vertex Pharmaceuticals Incorporated $VRTX

SG Americas Securities LLC lowered its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 66.7% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 56,982 shares of the pharmaceutical company’s stock after selling 114,017 shares during the quarter. SG Americas Securities LLC’s holdings in Vertex Pharmaceuticals were worth $25,445,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently made changes to their positions in the company. Motiv8 Investments LLC purchased a new position in Vertex Pharmaceuticals during the fourth quarter valued at approximately $26,000. Colonial Trust Co SC increased its stake in shares of Vertex Pharmaceuticals by 118.8% in the third quarter. Colonial Trust Co SC now owns 70 shares of the pharmaceutical company’s stock worth $27,000 after purchasing an additional 38 shares in the last quarter. Swiss RE Ltd. bought a new stake in shares of Vertex Pharmaceuticals during the 4th quarter valued at $28,000. Eagle Bay Advisors LLC bought a new stake in shares of Vertex Pharmaceuticals during the 4th quarter valued at $29,000. Finally, IMG Wealth Management Inc. lifted its stake in shares of Vertex Pharmaceuticals by 277.8% during the 4th quarter. IMG Wealth Management Inc. now owns 68 shares of the pharmaceutical company’s stock valued at $31,000 after buying an additional 50 shares in the last quarter. 90.96% of the stock is currently owned by institutional investors.

Insider Activity at Vertex Pharmaceuticals

In other news, CMO Carmen Bozic sold 6,988 shares of the company’s stock in a transaction that occurred on Tuesday, May 12th. The stock was sold at an average price of $450.00, for a total transaction of $3,144,600.00. Following the sale, the chief marketing officer directly owned 26,088 shares of the company’s stock, valued at $11,739,600. This represents a 21.13% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Sangeeta N. Bhatia sold 318 shares of the stock in a transaction that occurred on Monday, May 4th. The shares were sold at an average price of $423.73, for a total value of $134,746.14. Following the transaction, the director owned 4,924 shares of the company’s stock, valued at $2,086,446.52. This represents a 6.07% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 16,215 shares of company stock valued at $7,272,420. Insiders own 0.20% of the company’s stock.

Vertex Pharmaceuticals Stock Up 1.4%

Shares of VRTX stock opened at $475.20 on Thursday. The company’s fifty day simple moving average is $440.46 and its two-hundred day simple moving average is $453.72. Vertex Pharmaceuticals Incorporated has a 52 week low of $362.50 and a 52 week high of $507.92. The stock has a market cap of $120.61 billion, a P/E ratio of 28.19, a PEG ratio of 2.00 and a beta of 0.30.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its quarterly earnings data on Monday, May 4th. The pharmaceutical company reported $4.47 earnings per share for the quarter, beating analysts’ consensus estimates of $4.24 by $0.23. Vertex Pharmaceuticals had a return on equity of 23.86% and a net margin of 35.51%.The firm had revenue of $2.99 billion during the quarter, compared to analyst estimates of $2.99 billion. During the same quarter last year, the business posted $4.06 earnings per share. The business’s quarterly revenue was up 8.3% compared to the same quarter last year. On average, analysts anticipate that Vertex Pharmaceuticals Incorporated will post 17.02 EPS for the current fiscal year.

Vertex Pharmaceuticals News Summary

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Vertex received an upgrade-driven boost from commentary highlighting povetacicept as a potential new growth driver, reinforcing optimism that the company’s pipeline can support earnings beyond its cystic fibrosis franchise. Article Title
• Positive Sentiment: New pediatric data for CASGEVY showed strong clinical benefits and a consistent safety profile in children, supporting Vertex’s regulatory and commercial outlook for its CRISPR-based therapy. Article Title
• Positive Sentiment: Analyst sentiment remains constructive, with multiple firms reiterating bullish views and price targets above the current share price, suggesting continued institutional confidence in Vertex’s longer-term growth story. Article Title

Analyst Upgrades and Downgrades

VRTX has been the subject of a number of analyst reports. Jefferies Financial Group started coverage on Vertex Pharmaceuticals in a research note on Tuesday, March 10th. They issued a “buy” rating and a $580.00 price target for the company. Citigroup upped their price objective on Vertex Pharmaceuticals from $575.00 to $585.00 and gave the stock a “buy” rating in a research note on Tuesday, March 10th. Wall Street Zen upgraded Vertex Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday, June 20th. Barclays lifted their target price on Vertex Pharmaceuticals from $607.00 to $615.00 and gave the company an “overweight” rating in a research note on Wednesday, May 6th. Finally, HC Wainwright boosted their price target on Vertex Pharmaceuticals from $591.00 to $641.00 and gave the stock a “buy” rating in a report on Tuesday, March 10th. Twenty-two equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $555.91.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex’s marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.